» Articles » PMID: 1385114

The Human T Cell Antigen Gp39, a Member of the TNF Gene Family, is a Ligand for the CD40 Receptor: Expression of a Soluble Form of Gp39 with B Cell Co-stimulatory Activity

Overview
Journal EMBO J
Date 1992 Dec 1
PMID 1385114
Citations 110
Authors
Affiliations
Soon will be listed here.
Abstract

Signals delivered to B cells via CD40 can synergize with those provided by other B cell surface receptors to induce B cell proliferation and antibody class switching as well as modulate cytokine production and cell adhesion. Recently, it has been shown that the ligand for CD40 is a cell surface protein of approximately 39 kDa expressed by activated T cells, gp39. Here we report on the isolation and characterization of a cDNA clone encoding human gp39, a type II membrane protein with homology to TNF, and the construction and characterization of a soluble recombinant form of gp39. COS cell transfectants expressing gp39 synergized with either anti-CD20 mAb or PMA to drive strong B cell proliferation and alone were able to drive B cells to proliferate weakly. In all cases the B cell proliferation induced by gp39-expressing COS cells was reduced to background levels by the addition of soluble CD40. Unlike gp39-expressing COS cells, recombinant soluble gp39 was not mitogenic alone and required co-stimulation to drive B cell proliferation. These results suggest that B cells require a second signal besides gp39-CD40 to drive proliferation and that soluble gp39 alone in a non-membrane bound form is able to provide co-stimulatory signals to B cells.

Citing Articles

Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer.

Chen Y, Liu S, Yin X Am J Cancer Res. 2025; 15(1):217-232.

PMID: 39949922 PMC: 11815372. DOI: 10.62347/QTWJ8918.


Mechanotransduction governs CD40 function and underlies X-linked hyper-IgM syndrome.

Choi H, Travaglino S, Munchhalfen M, Gorg R, Zhong Z, Lyu J Sci Adv. 2024; 10(46):eadl5815.

PMID: 39546606 PMC: 11566996. DOI: 10.1126/sciadv.adl5815.


Developments in kidney xenotransplantation.

Xu H, He X Front Immunol. 2024; 14:1242478.

PMID: 38274798 PMC: 10808336. DOI: 10.3389/fimmu.2023.1242478.


Clinical and Immunological Features, Genetic Variants, and Outcomes of Patients with CD40 Deficiency.

Banday A, Nisar R, Patra P, Kaur A, Sadanand R, Chaudhry C J Clin Immunol. 2023; 44(1):17.

PMID: 38129705 PMC: 11252661. DOI: 10.1007/s10875-023-01633-1.


Mechanisms of CD40-dependent cDC1 licensing beyond costimulation.

Wu R, Ohara R, Jo S, Liu T, Ferris S, Ou F Nat Immunol. 2022; 23(11):1536-1550.

PMID: 36271147 PMC: 9896965. DOI: 10.1038/s41590-022-01324-w.


References
1.
Pennica D, Nedwin G, Hayflick J, Seeburg P, Derynck R, Palladino M . Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984; 312(5996):724-9. DOI: 10.1038/312724a0. View

2.
Aruffo A, Melnick M, Linsley P, Seed B . The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. J Exp Med. 1991; 174(4):949-52. PMC: 2118957. DOI: 10.1084/jem.174.4.949. View

3.
Aruffo A, Dietsch M, Wan H, Hellstrom K, Hellstrom I . Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines. Proc Natl Acad Sci U S A. 1992; 89(6):2292-6. PMC: 48643. DOI: 10.1073/pnas.89.6.2292. View

4.
Armitage R, Fanslow W, Strockbine L, Sato T, Clifford K, Macduff B . Molecular and biological characterization of a murine ligand for CD40. Nature. 1992; 357(6373):80-2. DOI: 10.1038/357080a0. View

5.
Vassalli P . The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992; 10:411-52. DOI: 10.1146/annurev.iy.10.040192.002211. View